✓ Translated by DotMD AI Clinical Council Source: BJU international • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #15049991 ↗

Randomized Controlled Trial: Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men

Original Paper Title: “Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • The 3 g/2% dose applied to the skin daily resulted in serum testosterone in the normal reference range in most hypogonadal men. Dose adjustments to either a lower or higher dose should shift serum testosterone concentration to the desired range in those who do not achieve this range with this dose.
  • Study Design & Sample: Randomized Controlled Trial published in BJU international (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in BJU international (2004), this randomized controlled trial evaluating human clinical outcomes investigated: To determine the regimen that would most effectively maintain serum testosterone concentrations in treated hypogonadal men within the normal reference range of 3-11.4 microg/L. Key clinical takeaway: The 3 g/2% dose applied to the skin daily resulted in serum testosterone in the normal reference range in most hypogonadal men. Dose adjustments to either a lower or higher dose should shift serum testosterone concentration to the desired range in those who do not achieve this range with this dose.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (BJU international, 2004-04-15; Randomized Controlled Trial; Rigor 82/100): The 3 g/2% dose applied to the skin daily resulted in serum testosterone in the normal reference range in most hypogonadal men. Dose adjustments to either a lower or higher dose should shift serum testosterone concentration to the desired range in those who do not achieve this range with this dose.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: testosterone-cypionate → Rx: testosterone → Rx: bufo-rana-bufo-bufo-cutaneous-gland → Condition: premature-ejaculation → Condition: erectile-dysfunction-due-to-arterial-insufficiency →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 15049991: Randomized Controlled Trial: Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men

3 of 3 Free Questions Remaining